Anavex Life Sciences Corporation (NASDAQ: AVXL)’s stock price has gone rise by 3.94 in comparison to its previous close of 9.13, however, the company has experienced a 15.17% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-26 that • First marketing authorization submission for blarcamesine NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced the submission of the blarcamesine (ANAVEX®2-73) MAA (Marketing Authorization Application) to the European Medicines Agency (EMA). The MAA submission is for the treatment of Alzheimer’s Disease.
Is It Worth Investing in Anavex Life Sciences Corporation (NASDAQ: AVXL) Right Now?
The stock has a 36-month beta value of 0.70. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AVXL is 82.10M, and at present, short sellers hold a 22.30% of that float. On November 26, 2024, the average trading volume of AVXL was 1.01M shares.
AVXL’s Market Performance
AVXL’s stock has seen a 15.17% increase for the week, with a 64.19% rise in the past month and a 61.39% gain in the past quarter. The volatility ratio for the week is 9.83%, and the volatility levels for the past 30 days are at 10.66% for Anavex Life Sciences Corporation The simple moving average for the past 20 days is 16.96% for AVXL’s stock, with a 78.04% simple moving average for the past 200 days.
Analysts’ Opinion of AVXL
Many brokerage firms have already submitted their reports for AVXL stocks, with Cantor Fitzgerald repeating the rating for AVXL by listing it as a “Neutral.” The predicted price for AVXL in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on December 06, 2022 of the previous year 2022.
Berenberg, on the other hand, stated in their research note that they expect to see AVXL reach a price target of $40. The rating they have provided for AVXL stocks is “Buy” according to the report published on June 23rd, 2022.
BTIG Research gave a rating of “Buy” to AVXL, setting the target price at $35 in the report published on September 23rd of the previous year.
AVXL Trading at 44.99% from the 50-Day Moving Average
After a stumble in the market that brought AVXL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.19% of loss for the given period.
Volatility was left at 10.66%, however, over the last 30 days, the volatility rate increased by 9.83%, as shares surge +66.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +73.97% upper at present.
During the last 5 trading sessions, AVXL rose by +15.28%, which changed the moving average for the period of 200-days by +54.70% in comparison to the 20-day moving average, which settled at $8.11. In addition, Anavex Life Sciences Corporation saw 1.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVXL starting from Donhauser Peter D.O., who purchase 2,835 shares at the price of $3.64 back on Jun 14 ’24. After this action, Donhauser Peter D.O. now owns 5,000 shares of Anavex Life Sciences Corporation, valued at $10,319 using the latest closing price.
Thomas Steffen, the Director of Anavex Life Sciences Corporation, purchase 5,000 shares at $4.52 during a trade that took place back on May 15 ’24, which means that Thomas Steffen is holding 5,000 shares at $22,600 based on the most recent closing price.
Stock Fundamentals for AVXL
The total capital return value is set at -0.37. Equity return is now at value -30.03, with -27.74 for asset returns.
Currently, EBITDA for the company is -55.76 million with net debt to EBITDA at 7.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.04.
Conclusion
To sum up, Anavex Life Sciences Corporation (AVXL) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
